SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade, M.D., medical director of pulmonology. In this role, Dr. Bhorade will lead medical affairs for Veracyte’s pulmonology products, including the Percepta® Bronchial Classifier and Envisia™ Genomic Classifier. Dr. Bhorade will report to Giulia Kennedy, Ph.D., Veracyte’s chief scientific and medical officer.
Prior to joining Veracyte, Dr. Bhorade was professor of medicine and the medical director of the Lung Transplant Program in the Pulmonary and Critical Care Division at Northwestern University Feinberg School of Medicine. During her tenure at Northwestern University, Dr. Bhorade launched its Lung Transplant Program and provided research and clinical expertise as a principal faculty member of the Interstitial Lung Disease Program. She also initiated the Lung Transplant Program at the University of Chicago and served as its medical director.
“We are thrilled to welcome Sangeeta to the Veracyte team,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “As a leader in the field of pulmonology, she brings a wealth of expertise and experience to our pulmonary program and will be instrumental in helping us advance early detection, improve diagnosis and inform treatment decisions for patients.”
“I am excited to join Veracyte and provide clinical and research expertise to help shape the company’s portfolio of pulmonary diagnostics,” said Dr. Bhorade. “I look forward to helping patients get access to these scientifically advanced tests that may help improve their health outcomes and cost of care."
Dr. Bhorade is board certified in pulmonary and critical care medicine. She received her B.A. from the University of Chicago and her medical degree from the University of Chicago Pritzker School of Medicine. Dr. Bhorade has been voted a “Top Doctor” in pulmonology by U.S. News and World Report for the past seven years.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized five genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.